EMEA Point-Of-Care Diagnostics Market Growth, Size, Trends ,Analysis and Segment Forecast to 2034
EMEA Point-Of-Care Diagnostics Market Growth, Size, Trends Analysis - By Product, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: HLCA25206 | Pages: 1 - 244 | Formats*: |
| Category : Healthcare | |||
EMEA Point-Of-Care Diagnostics Market Introduction and Overview
According to SPER Market Research, the EMEA Point-Of-Care Diagnostics Market is estimated to reach USD 25.81 billion by 2034 with a CAGR of 6.43%.
The report includes an in-depth analysis of the EMEA Point-Of-Care Diagnostics Market, including market size and trends, product mix, Applications, and supplier analysis. The EMEA Point-Of-Care Diagnostics Market was valued at USD 13.84 billion in 2024 and is expected to grow at a CAGR of 6.43% from 2025 to 2034. The expanding elderly population, combined with high prevalence rates of chronic diseases, has principally fuelled market expansion. Diabetes, cardiovascular disease, and viral disorders such as HIV, TB, and influenza have all raised the need for quick and precise diagnostics. PoC diagnostics, with their capacity to offer instantaneous results at the patient's location, have become important in properly managing many health issues.
By Product Insights
Glucose testing is the most popular category in the point-of-care (PoC) diagnostics market, owing to the increasing prevalence of diabetes and the need for continuous monitoring. This need has led to the widespread use of point-of-care glucose testing devices such as glucose meters, continuous glucose monitoring (CGM) systems, and associated consumables such as testing strips and lancets. Innovations in minimally invasive CGM technologies and smart glucose meters that interact with digital health platforms have increased accessibility and efficiency. These developments enable real-time monitoring, allowing people to better control their conditions and make educated health decisions.
By End User Insights
The hospital sector led the market in owing to the availability of qualified medical practitioners in hospital radiology departments. In addition, governments and organisations are providing financing and assistance for radiopharmaceutical development and commercialisation, which is fuelling market growth. The hospital sector is estimated to account for a sizable portion of the market over the forecast period.
Regional Insights
Germany is a major player in the point-of-care diagnostics market, owing to the increasing prevalence of chronic diseases such as diabetes, cardiovascular disease, and respiratory sickness. The efficiency and immediacy of PoC testing enable speedier clinical decision-making, resulting in better patient outcomes and less strain on traditional laboratory systems. Germany's well-developed healthcare infrastructure and supportive government policies have played an important role in promoting PoC diagnostics through research funding, provider incentives, and public awareness programs, encouraging wider usage across healthcare settings.
Market Competitive Landscape
The EMEA Point-Of-Care Diagnostics Market is dominated by established players such as Abbott, BD (Becton Dickinson), BIOMÉRIEUX, Danaher Corporation, F. Hoffmann-La Roche Ltd, as well as a number of small and medium-sized companies. These market participants compete fiercely, with some operating in multiple locations and having significant consumer bases. Furthermore, the market is consolidated, with a few large-scale vendors owning the majority of the market. Leading corporations have invested much in thorough research and development, largely to create more cutting-edge products.
Recent Developments:
In July 2024, EKF Diagnostics Holdings plc introduced the Biosen C-Line, a more sophisticated version of its premier quick benchtop glucose and lactate analyser. The Biosen C-Line provides a secure and rapid mechanism for connecting POC devices to hospital and laboratory IT systems, ensuring that doctors can swiftly and securely obtain patient results.
Across June 2023, Sysmex Corporation introduced "the System," a testing system, across Europe. It detects the absence or presence of bacteria and analyses the efficacy of antimicrobials using urine samples from patients suspected of having urinary tract infections.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By End User |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Abbott, BD (Becton Dickinson), BIOMÉRIEUX, Danaher Corporation, F. Hoffmann-La Roche Ltd, Nova Biomedical, QIAGEN, Siemens Healthcare Private Limited, Trividia Health, Inc, Werfen. |
Key Topics Covered in the Report
- EMEA Point-Of-Care Diagnostics Market Size (FY’2021-FY’2034)
- Overview of EMEA Point-Of-Care Diagnostics Market
- Segmentation of EMEA Point-Of-Care Diagnostics Market by Product (Glucose Testing, Hb1Ac Testing, Coagulation Testing, Fertility/Pregnancy, Vikram, Cardiac Markers, Thyroid Stimulating Hormone, Haematology, Primary Care Systems)
- Segmentation of EMEA Point-Of-Care Diagnostics Market by End User (Hospitals, Home, Assisted Living Healthcare Facilities, Laboratory, Others.)
- Statistical Snap of EMEA Point-Of-Care Diagnostics Market
- Expansion Analysis of EMEA Point-Of-Care Diagnostics Market
- Problems and Obstacles in EMEA Point-Of-Care Diagnostics Market
- Competitive Landscape in the EMEA Point-Of-Care Diagnostics Market
- Details on Current Investment in EMEA Point-Of-Care Diagnostics Market
- Competitive Analysis of EMEA Point-Of-Care Diagnostics Market
- Prominent Players in the EMEA Point-Of-Care Diagnostics Market
- SWOT Analysis of EMEA Point-Of-Care Diagnostics Market
- EMEA Point-Of-Care Diagnostics Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.EMEA Point-Of-Care Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in EMEA Point-Of-Care Diagnostics Market
7.EMEA Point-Of-Care Diagnostics Market by Product (USD Million) 2021-2034
7.1.Glucose Testing7.2.Hb1Ac Testing7.3.Coagulation Testing7.4.Fertility/Pregnancy7.5.Vikram7.6.Cardiac Markers7.7.Thyroid Stimulating Hormone7.8.Haematology7.9.Primary Care Systems
8.EMEA Point-Of-Care Diagnostics Market by End UseR (USD Million) 2021-2034
8.1.Hospitals8.2.Home8.3.Assisted Living Healthcare Facilities8.4.Laboratory8.5.Others
9.EMEA Point-Of-Care Diagnostics Market (USD Million) 2021-2034
9.1.EMEA Point-Of-Care Diagnostics Market Size and Market Share
10.EMEA Point-Of-Care Diagnostics Market by Region, (USD Million) 2021-2034
10.1.Europe
10.1.1.UK10.1.2.Germany10.1.3.France10.1.4.Italy10.1.5.Spain10.1.6.Denmark10.1.7.Sweden10.1.8.Norway
10.2.Middle East and Africa
10.2.1.South Africa10.2.2.UAE10.2.3.Saudi Arabia10.2.4.Kuwait
11.Company Profile
11.1.Abbott11.1.1.Company details11.1.2.Financial outlook11.1.3.Product summary11.1.4.Recent developments11.2.BD (Becton Dickinson)11.2.1.Company details11.2.2.Financial outlook11.2.3.Product summary11.2.4.Recent developments11.3.BIOMÉRIEUX11.3.1.Company details11.3.2.Financial outlook11.3.3.Product summary11.3.4.Recent developments11.4.Danaher Corporation11.4.1.Company details11.4.2.Financial outlook11.4.3.Product summary11.4.4.Recent developments11.5.F. Hoffmann-La Roche Ltd11.5.1.Company details11.5.2.Financial outlook11.5.3.Product summary11.5.4.Recent developments11.6.Nova Biomedical11.6.1.Company details11.6.2.Financial outlook11.6.3.Product summary11.6.4.Recent developments11.7.QIAGEN11.7.1.Company details11.7.2.Financial outlook11.7.3.Product summary11.7.4.Recent developments11.8.Siemens Healthcare Private Limited11.8.1.Company details11.8.2.Financial outlook11.8.3.Product summary11.8.4.Recent developments11.9.Trividia Health, Inc11.9.1.Company details11.9.2.Financial outlook11.9.3.Product summary11.9.4.Recent developments11.10.Werfen11.10.1.Company details11.10.2.Financial outlook11.10.3.Product summary11.10.4.Recent developments11.11.Others
12.Conclusion
13.List of Abbreviations
14.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
EMEA Point-Of-Care Diagnostics Market is projected to reach USD 25.81 by 2034, growing at a CAGR of 6.43 % during the forecast period.
EMEA Point-Of-Care Diagnostics Market size from 2025. The Market is expected to reach USD 25.81 by 2034, at a CAGR of 6.43% during the forecast period.
EMEA Point-Of-Care Diagnostics Market CAGR of 6.43% during the forecast period.
You can get the sample pages by clicking the link - Click Here
EMEA Point-Of-Care Diagnostics Market size is USD 25.81 from 2025 to 2034.
EMEA Point-Of-Care Diagnostics Market covered By Product, By End User
The North America is anticipated to have the highest Market share in the EMEA Point-Of-Care Diagnostics Market .
"
Abbott, BD (Becton Dickinson), BIOMÉRIEUX, Danaher Corporation, F. Hoffmann-La Roche Ltd, Nova Biomedical, QIAGEN, Siemens Healthcare Private Limited, Trividia Health, Inc, Werfen."
The report includes an in-depth analysis of the EMEA Point-Of-Care Diagnostics Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
